Q-omics provides the consensus-scored ARID3B profile across patient tissues and cancer cell-line models. ARID3B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARID3B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ARID3B RNA expression shows 19,794 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ARID3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARID3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARID3B survival associations across molecular data types. ARID3B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARID3B RNA expression–survival associations across cancer types. High ARID3B expression shows unfavorable associations in ACC, LGG, LIHC and COAD, but favorable associations in SCLC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARID3B RNA expression.
This table summarizes ARID3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARID3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARID3B shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, KIRC and UCEC. The HNSC box plot shows higher ARID3B RNA expression in tumor versus normal tissue (log2 FC = +0.785, t-test p < 0.001).
This table shows molecular features associated with ARID3B in patient tissues and cancer cell lines. In patient samples, ARID3B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARID3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
